Michele Zeverino

Dr. Michele Zeverino

Institute of Radiation Physics, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
RJRaphaël Jumeau
Raphaël Jumeau
MOMahmut Ozsahin
Mahmut Ozsahin
JSJuerg Schwitter
Juerg Schwitter
VVVéronique Vallet
Véronique Vallet
FDFrédéric Duclos
Frédéric Duclos
Jean BourhisJean Bourhis
Jean Bourhis

17 May 2017 in Acta Neurochirurgica
Verified
Journal Article
Open access
PDF file
RDRoy Thomas Daniel
Roy Thomas Daniel
CTConstantin Tuleasca
Constantin Tuleasca
MGMercy George
Mercy George
EPEtienne Pralong
Etienne Pralong
LSLuis Schiappacasse
Luis Schiappacasse
MLMarc Levivier
Marc Levivier
Objective To perform planned subtotal resection followed by gamma knife surgery (GKRS) in a series of patients with large vestibular schwannoma (VS), aiming at an optimal functional outcome for facial and cochlear nerves. Methods Patient characteristics, surgical and dosimetric features, and outcome were collected prospectively at the time of treatment and during the follow-up. Results A consecutive series of 32 patients was treated between July 2010 and June 2016. Mean follow-up after surgery was 29 months (median 24, range 4–78). Mean presurgical tumor volume was 12.5 cm3 (range 1.47–34.9). Postoperative status showed normal facial nerve function (House–Brackmann I) in all patients. In a subgroup of 17 patients with serviceable hearing before surgery and in which cochlear nerve preservation was attempted at surgery, 16 (94.1%) retained serviceable hearing. Among them, 13 had normal hearing (Gardner–Robertson class 1) before surgery, and 10 (76.9%) retained normal hearing after surgery. Mean duration between surgery and GKRS was 6.3 months (range 3.8–13.9). Mean tumor volume at GKRS was 3.5 cm3 (range 0.5–12.8), corresponding to mean residual volume of 29.4% (range 6–46.7) of the preoperative volume. Mean marginal dose was 12 Gy (range 11–12). Mean follow-up after GKRS was 24 months (range 3–60). Following GKRS, there were no new neurological deficits, with facial and hearing functions remaining identical to those after surgery in all patients. Three patients presented with continuous growth after GKRS, were considered failures, and benefited from the same combined approach a second time. Conclusion Our data suggest that large VS management, with planned subtotal resection followed by GKRS, might yield an excellent clinical outcome, allowing the normal facial nerve and a high level of cochlear nerve functions to be retained. Our functional results with this approach in large VS are comparable with those obtained with GKRS alone in small- and medium-sized VS. Longer term follow-up is necessary to fully evaluate this approach, especially regarding tumor control.

30 January 2017 in Medical Physics
Verified
Journal Article
Closed access
PDF file
MZMichele Zeverino
Michele Zeverino
MJMaud Jaccard
Maud Jaccard
DPDavid Patin
David Patin
NRNick Ryckx
Nick Ryckx
MMMaud Marguet
Maud Marguet
RMRaphaël Moeckli
Raphaël Moeckli

1 March 2011 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
RCRenzo CORVO
Renzo CORVO
MZMichele Zeverino
Michele Zeverino
Stefano VaggeStefano Vagge
Stefano Vagge
SAStefano Agostinelli
Stefano Agostinelli
SBSalvina Barra
Salvina Barra
ABAndrea Bacigalupo
Andrea Bacigalupo

1 February 2016 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
NPNicolas Péguret
Nicolas Péguret
MOMahmut Ozsahin
Mahmut Ozsahin
MZMichele Zeverino
Michele Zeverino
BBBastien Belmondo
Bastien Belmondo
ADAndré Durham
André Durham
Jean BourhisJean Bourhis
Jean Bourhis

1 December 2016 in Journal of Neurosurgery
Verified
Journal Article
Closed access
CTConstantin Tuleasca
Constantin Tuleasca
MGMercy George
Mercy George
MFMohamed Faouzi
Mohamed Faouzi
LSLuis Schiappacasse
Luis Schiappacasse
HLHenri-Arthur Leroy
Henri-Arthur Leroy
MLMarc Levivier
Marc Levivier
OBJECTIVE: Vestibular schwannomas (VSs) represent a common indication of Gamma Knife surgery (GKS). While most studies focus on the long-term morbidity and adverse radiation effects (AREs), none describe the acute clinical AREs that might appear on a short-term basis. These types of events are investigated, and their incidence, type, and outcomes are reported in the present paper.METHODS: The included patients were treated between July 2010 and March 2016, underwent at least 6 months of follow-up, and presented with a disabling symptom during the first 6 months after GKS that affected their quality of life. The timing of appearance, as well as the type of main symptom and outcome, were noted. The prescribed dose was 12 Gy at the margin.RESULTS: Thirty-five (22%) of 159 patients who fulfilled the inclusion criteria had acute clinical AREs. The mean followup period was 30 months (range 6–49.2 months). The mean time of appearance was 37.9 days (median 31 days; range 3–110 days). In patients with de novo symptoms, the more frequent symptoms were vertigo (n = 4; 11.4%) and gait disturbance (n = 3; 8.6%). The exacerbation of a preexisting symptom was more frequently related to hearing loss (n = 10; 28.6%), followed by gait disturbance (n = 7; 20%) and vertigo (n = 3, 8.6%). In the univariate logistic regression analysis, the following factors were statistically significant: age (p = 0.002; odds ratio [OR] 0.96), hearing at baseline by Gardner-Robertson (GR) class (p = 0.006; OR 0.21), pure tone average at baseline (p = 0.006; OR 0.97), and Koos grade at baseline (with Koos Grade I used as a reference) (for Koos Grade II, OR 0.17 and p = 0.002; for Koos Grade III, OR 0.42 and p = 0.05). The following were not statistically significant but showed a tendency toward significance: the number of isocenters (p = 0.06; OR 0.94) and the maximal dose received by the cochlea (p = 0.07; OR 0.74). Fractional polynomial regression analysis showed a nonlinear relationship between the outcome and the radiation dose rate (minimum reached at a cutoff of 2.5 Gy/minute) and the maximal vestibular dose (maximum reached at a cutoff of 8 Gy), but the small sample size precludes a detailed analysis of the former. The clinical acute AREs disappeared in 32 (91.4%) patients during the first 6 months after appearance. Permanent and somewhat disabling morbidity was found in 3 cases (1.9% from the whole series): 1 each with complete hearing loss (GR Class I before and V after), hemifacial spasm (persistent but alleviated), and dysgeusia.CONCLUSIONS: Acute effects after radiosurgery for VS are not rare. They concern predominantly de novo vertigo and gait disturbance and the exacerbation of preexistent hearing loss. In de novo vestibular symptoms, a vestibular dose of more than 8 Gy is thought to play a role. In most cases, none of these effects are permanent, and they will ultimately improve or disappear with steroid therapy. Permanent AREs remain very rare.